ProCE Banner Activity

Phase I/II Study of JAK1/2 Inhibitor Baricitinib in Refractory Chronic GVHD

Slideset Download
Conference Coverage
Baricitinib appears to be well tolerated and effective for patients with therapy-refractory severe chronic GVHD, demonstrating rapid and durable responses.

Released: December 17, 2020

Expiration: December 16, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology